Thapa, B., Henderson, N., Tagawa, S. T., Hwang, C., Sokolova, A. O., Bilen, M. A., … Kilari, D. (2024). 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). In Annals of Oncology (Vol. 35, pp. S991–S991). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.1724

Thapa, B., N. Henderson, S. T. Tagawa, C. Hwang, A. O. Sokolova, M. A. Bilen, P. M. Coelho Barata, et al. “1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC).” In Annals of Oncology, 35:S991–S991. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.1724.

Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, et al. 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). In: Annals of Oncology. Elsevier BV; 2024. p. S991–S991.

Thapa, B., et al. “1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC).” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S991–S991. Crossref, doi:10.1016/j.annonc.2024.08.1724.

Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, Coelho Barata PM, Nguyen CB, Tripathi A, Ayanambakkam A, Graham LS, Zakharia Y, Koshkin VS, Heath E, Dorff TB, Armstrong AJ, McKay RR, Alva AS, Schweizer M, Kilari D. 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). Annals of Oncology. Elsevier BV; 2024. p. S991–S991.